rare-disease

Shire to buy Dyax for $5.9 billion, still wants Baxalta

Shire Plc has agreed to buy U.S. rare disease specialist Dyax Corp for about $5.9 billion – and potentially up to $6.5 billion – while still pursuing a five times larger unsolicited bid for Baxalta Inc . Given its existing HAE presence, Ornskov acknowledged the deal would be scrutinized by antitrust authorities and he said Shire was already preparing for this.

Here is the original: 
Shire to buy Dyax for $5.9 billion, still wants Baxalta